Brief: MHRA Says Licensed Brensocatib as First Drug for Non-Cystic Fibrosis Bronchiectasis in Patients Aged 12+
23/02/2026 09:35
Feb 23 (Reuters) - MHRA: MHRA: BRENSOCATIB LICENSED AS FIRST MEDICINE SPECIFICALLY DESIGNED TO TREAT NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS AND OLDER Source text: [ID:] Further company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector